Eli Lilly, Boehringer revise terms in diabetes drug pact; Celgene expands cancer drug development pact;

@FierceBiotech: Armed with $48M bankroll, Aileron sets sights on p53 tumor target. Article | Follow @FierceBiotech

@JohnCFierce: $JNJ in China, deals getting struck on drug rights. Lots coming in Asia for biopharma. It's the new, new thing | Follow @JohnCFierce

@DamianFierce: "Categorical" second only to "fundamental" in corporate nonsensespeak--$AEGR. More from TheStreet | Follow @DamianFierce

@EmilyMFierce: Brain cells reprogrammed from skin cells offer treatment hope for Huntington's. FierceBiotech Research story | Follow @EmilyMFierce

> Eli Lilly ($LLY) and Boehringer Ingelheim have revised the terms of their big diabetes drug alliance. While the two will continue to co-promote in 17 top global markets, all other countries will be handled by the company that brought them to the alliance. Release

> Toronto-based Triphase Accelerator Corporation has expanded its collaboration with Celgene ($CELG), adding a Phase I development program that will explore combining an intravenous formulation of marizomib with bevacizumab in glioblastoma. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Welch Allyn partners with startup Gentag to create wearable devices. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED: Dx company Alere sells its health services unit for $600M amid continued restructuring. More | Follow @VarunSaxena2

@EmilyWFierce: Au revoir, Viehbacher. Reuters article | Follow @EmilyWFierce

> J&J Innovation's Ken Drazan on the future of med tech. Editor's Corner

> Medtronic announces first U.S. implant of investigational aortic heart valve. Article

Pharma News

@FiercePharma: Top-read in FiercePharmaManufacturing Tues: Production issues for $GSK, Sanofi delay flu vaccines in the U.S. Article | Follow @FiercePharma

@EricPFierce: Ranbaxy's Ohm Laboratories plant comes to the rescue in last quarter, turning bottom line from red to black. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Pharma's top 10 M&A deals of H1 2014. Feature | Follow @CarlyHFierce

> Like Novartis before it, AstraZeneca benefits big time from Ranbaxy issues. Report

> Sanofi canned its outspoken CEO. Will the board go French with a replacement? More

Drug Delivery News

> BDSI aiming to develop injectable buprenorphine. Item

> Harvard team uses stem cells to deliver toxic doses to cancer cells. Report

> Microscale fibers may have many drug-delivery uses. Story

> Pfizer to withdraw from partnership to develop tamper-proof oxycodone formulation. Article

Diagnostics News

> Johns Hopkins scientists develop real-time diagnostic system for drug-resistant bacteria. More

> FDA grants bioMérieux emergency authorization for one-hour Ebola Dx. Item

> 'See-through' sensors for the brain are transparent to imaging diagnostics. Story

> French scientists roll out rapid diagnostic test for Ebola. Article

Pharma Marketing News

> Love to hate Mr. Mucus? The Mucinex snot monster is back with a McCann makeover. Report

> For Novartis' respiratory ambitions, it's a tale of 'two worlds.' Story

> Sanofi board ousts CEO, aiming for a more 'cooperative' chief. Item

> Who's the diabetes price-cutting culprit: Lilly, Sanofi or Novo? More

> Orphan drug pricing for non-orphan meds? Express Scripts is looking at you, Gilead. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.